Searchable abstracts of presentations at key conferences in endocrinology

ea0011p302 | Diabetes, metabolism and cardiovascular | ECE2006

Renal expression of alpha-ENaC is increased in testosterone treated rats

Kienitz T , Allolio B , Strasburger CJ , Quinkler M

Introduction: There is no difference in blood pressure between boys and girls, but following puberty, blood pressure increases more in men than in women. The higher blood pressure and stronger progression of hypertension in men is associated with a higher risk and mortality for cardiovascular diseases than in women. Androgens are known to play an important role in renal tubular epithelial cell growth, hypertrophy and erythropoetin production and may be important determinants o...

ea0011p482 | Endocrine tumours and neoplasia | ECE2006

48 h appears as sufficient duration of fasting in the diagnosis of insulinoma – a single centre experience with 23 cases

Quinkler M , Strehlow F , Biering H , Pirlich M , Gerl H , Strasburger CJ , Ventz M

Insulinoma causes fasting hypoglycemia due to inappropriate insulin secretion. The diagnosis of insulinoma is based on Whipple’s triad (1. symptoms precipitated by fasting with 2. associated blood sugars of 50 mg/dl or less and 3. relief of symptoms by glucose administration) during a supervised 72 h fasting test. After introducing reliable assays for measurement of insulin and proinsulin, there is an ongoing debate whether a 48 h fasting test is sufficient for diagnosis ...

ea0011p511 | Endocrine tumours and neoplasia | ECE2006

The latest safety and efficacy data of patients treated with Pegvisomant

Schreiber I , Forssmann K , Buchfelder M , Droste M , Mann K , Saller B , Strasburger CJ

The German Acrostudy is at present the largest database on acromegalics (n=184) treated with pegvisomant (Somavert®). 91% pts underwent pituitary surgery, 45% received radiation therapy, and previous medical therapy included dopamine agonists (56%), octreotide (90%) and/or lanreotide (10%). Common concomitant diseases at baseline were hypertension (47.0%), diabetes mellitus (31.7%), and gallstone disease (25.6%). Efficacy analysis was performed in 134 pt...

ea0011p626 | Neuroendocrinology and behaviour | ECE2006

The influence of a GH receptor antagonist (GHRA) on the relationship between GH and IGF-I in adults with severe growth hormone deficiency (AGHD)

Pokrajac A , Berg CA , Bidlingmaier M , Strasburger CJ , Shalet SM , Trainer PJ

Approximately 50% of patients with severe AGHD (defined by the international consensus criteria, peak GH <3 ng/ml) have a normal age- and gender-related IGF-I. It remains unclear whether in these individuals IGF-I is GH-dependent.We performed a double-blind, randomised, placebo-controlled, cross-over study on the effect of pegvisomant (20 mg daily for 14 days) on the relationship between GH and IGF-I in 3 age-, gender- and BMI-matched cohorts (Norms:...

ea0011p627 | Neuroendocrinology and behaviour | ECE2006

Can adults with severe growth hormone deficiency (AsGHD) and a low IGF-I be distinguished from those with a normal IGF-I?

Berg CA , Pokrajac A , Bidlingmaier M , Strasburger CJ , Mann K , Shalet SM , Trainer PJ

Approximately 50% of patients with severe AGHD (defined by the international consensus criteria, peak GH <3 ng/ml) have a normal age- and gender-related IGF-I. It remains unclear whether in these individuals IGF-I is GH-dependent. We performed a double-blind, randomised, placebo-controlled, cross-over study on the effect of pegvisomant (20 mg daily for 14 days) on the relationship between GH and IGF-I in 3 age-, gender- and BMI-matched cohorts (Norms: 5 GHD patients with n...